Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:C12N15/50

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.111239392一种新型冠状病毒肺炎(COVID-19)血清学诊断试剂盒
CN 05.06.2020
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
Appl.No 202010121435.7 Applicant 浙江诺迦生物科技有限公司 Inventor 范春雷
本发明公开了一种新型冠状病毒肺炎(COVID‑19)血清学诊断试剂盒,包括S‑IgM/IgG和N‑IgM/IgG两种试纸条,组装成一个双抗原四联检试剂盒,可以针对新型冠状病毒肺炎COVID‑19病人血清抗新型冠状病毒棘突蛋白S的IgM/IgG抗体及抗新型冠状病毒核衣壳蛋白N的IgM/IgG抗体四个指标同时检测。本发明的试剂盒通过量子点荧光标记和多级偶联放大信号提高检测灵敏度、通过双抗原四联检提高检测准确性、通过建立病毒灭活系统保障检测过程中的生物安全性。试剂盒适合包括全血、血浆、血清检测,可应用于新型冠状病毒肺炎(COVID‑19)血清学诊断。
2.111239394一种基于混合抗原快速检测新型冠状病毒抗体试剂盒
CN 05.06.2020
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
Appl.No 202010156804.6 Applicant 四川省人民医院 Inventor 杨正林
本发明公开了一种基于混合抗原快速检测新型冠状病毒抗体试剂盒,包括COVID‑19核衣壳蛋白抗原胶体金和COVID‑19纤突蛋白抗原胶体金。将该试剂盒用于用于诊断新型冠状肺炎,操作简便,可直接将COVID‑19核衣壳蛋白抗原胶体金和COVID‑19纤突蛋白抗原胶体金混合作为整体进行检测,或者检测时直接将COVID‑19核衣壳蛋白抗原胶体金和COVID‑19纤突蛋白抗原胶体金混合进行检测,检测灵敏度高,利于疫情的有效控制。
3.111218459一种以人复制缺陷腺病毒为载体的重组新型冠状病毒疫苗
CN 02.06.2020
Int.Class C12N 15/50
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
50Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
Appl.No 202010193587.8 Applicant 中国人民解放军军事科学院军事医学研究院 Inventor 陈薇
本发明提供一种以人5型复制缺陷腺病毒为载体的新型冠状病毒疫苗。所述疫苗以E1、E3联合缺失的复制缺陷型人5型腺病毒为载体,以整合腺病毒E1基因的HEK293细胞为包装细胞系,携带的保护性抗原基因是经过优化设计的2019新型冠状病毒(SARS‑CoV‑2)S蛋白基因(Ad5‑nCoV)。S蛋白基因经优化后,在转染细胞中的表达水平显著升高。该疫苗在小鼠和豚鼠模型上均具有良好的免疫原性,能在短时间内诱导机体产生强烈的细胞及体液免疫反应。hACE2转基因小鼠上的保护效果研究显示,单次免疫Ad5‑nCoV14天后能够明显降低肺组织内部的病毒载量,说明该疫苗对2019新型冠状病毒具有良好的免疫保护效果。此外,该疫苗制备快速简便,可在短期内实现大规模生产用于应对突发疫情。
4.111218458编码SARS-CoV-2病毒抗原的mRNA和疫苗及疫苗的制备方法
CN 02.06.2020
Int.Class C12N 15/50
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
50Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
Appl.No 202010125774.2 Applicant 珠海丽凡达生物技术有限公司 Inventor 彭育才
本发明提供了一种编码SARS‑CoV‑2病毒抗原的mRNA和疫苗及疫苗的制备方法,涉及疫苗的技术领域。该编码SARS‑CoV‑2病毒抗原的mRNA至少含有编码SARS‑CoV‑2病毒的S蛋白和N蛋白中的至少一个蛋白,和/或至少一个蛋白的片段的编码区,该mRNA递送至体内可以使机体产生免疫反应。
5.111187782猪Delta冠状病毒病毒样颗粒及其制备方法和应用
CN 22.05.2020
Int.Class C12N 15/50
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
50Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
Appl.No 202010064111.4 Applicant 上海交通大学 Inventor 严亚贤
本发明提供了一种猪Delta冠状病毒病毒样颗粒及其制备方法和应用,首先设计并扩增猪Delta冠状病毒结构蛋白基因,并利用结构蛋白基因构建重组穿梭质粒,利用重组穿梭质粒构建重组杆粒,将重组杆粒转染Sf9细胞,得到表达猪Delta冠状病毒结构蛋白的重组杆状病毒,将重组杆状病毒感染Sf9细胞,纯化,得到猪Delta冠状病毒样颗粒;本发明的制备方法使用无血清培养的Sf9细胞表达制备,结合蔗糖密度溶液超速离心获得PDCoV‑VLP病毒样颗粒,该PDCoV‑VLP病毒样颗粒具有完整性,免疫原性好,免疫动物产生抗体滴度和安全性高的优点,可用于猪Delta冠状病毒病毒病的预防,故具有良好的开发和应用前景。
6.111154779一种MERS RNA核酸参考品的制备方法
CN 15.05.2020
Int.Class C12N 15/50
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
50Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
Appl.No 201910978081.5 Applicant 中国科学院武汉病毒研究所 Inventor 危宏平
本发明公开了一种MERS RNA核酸参考品的制备方法,所述制备方法分别将MERS的upE基因和ORF1a基因串联以及ORF1b和N基因串联整合到慢病毒的表达质粒载体中,将构建的两个表达质粒与三个包装质粒分别在工程大肠杆菌菌株中扩增,得到大量的质粒后,再将构建的两个表达质粒分别和三个包装质粒共同转染至HEK293T细胞中,经细胞表达后得到大量的包装了MERS RNA的慢病毒颗粒,本发明涉及基因工程技术领域。该MERS RNA核酸参考品的制备方法,制备的颗粒作为MERS RNA检测的阳性参考品,能很好地模拟从实际样本中提取病毒核酸RNA到核酸检测的整个过程,此外,将该病毒颗粒通过冻干保护剂进行冻干后得到的冻干粉,非常稳定,在45℃放置四周拷贝数基本不变。
7.111153991一种人SARS-CoV-2单克隆抗体及其制备方法和应用
CN 15.05.2020
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No 202010120349.4 Applicant 北京博奥森生物技术有限公司 Inventor 赵风强
本发明公开了一种人SARS‑CoV‑2单克隆抗体,其制备方法为:以SARS‑CoV Nucleocapsid重组蛋白为免疫原,免疫BALB/c小鼠,进行小鼠脾细胞和鼠骨髓瘤细胞融合及亚克隆,再经商品化的产品SARS‑CoV‑2 Nucleocapsid及MERS Nucleocapsid进行大量反复筛选以及细胞株的驯化,最终成功获得可分泌高亲和力、高特异性抗SARS‑CoV‑2 N单克隆抗体杂交瘤细胞株,最后腹水制备及纯化,获得单克隆抗体;SARS‑CoV Nucleocapsid重组蛋白的氨基酸序列如SEQ ID NO.1所示。本发明还公开了该单克隆抗体在制备SARS‑CoV‑2病毒检测产品中的应用,在制备抑制SARS‑CoV‑2病毒的药物中的应用。本发明的单克隆抗体可通过双抗体夹心法对人体咽拭子/肺部分泌物等样本中SARS‑CoV‑2进行检测,可应用于SARS‑CoV‑2检测试剂盒,适用于SARS‑CoV‑2病毒感染的诊断、防控,病毒的科学研究等。
8.111053899一种双价支气管炎核酸疫苗、制备方法及用途
CN 24.04.2020
Int.Class A61K 39/295
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
295Polyvalent viral antigens; Mixtures of viral and bacterial antigens
Appl.No 202010020583.X Applicant 徐晓芳 Inventor 高江明
本发明提供了一种双价支气管炎核酸疫苗、制备方法及用途,其核心表达区仅为1491bp,序列前引入了分泌信号肽,表达序列引入Kozak序列,并选用含有禽启动子序列质粒,去除了不易成为抗原的疏水区,采用M41和H120特征蛋白拼接,中间连有lingker序列,可刺激产生针对两种毒株的中和抗体,弥补了传染性支气管炎病毒免疫交叉性差的弱点;选用鼠伤寒沙门氏菌作为载体,对宿主本身没有感染隐患,但可支持核酸疫苗长期表达,以达到长期免疫效果;疫苗的免疫方式为经口免疫,可以添加到饲料内,使用方便优于滴鼻或注射免疫方式;该疫苗制备为发酵后收集培养物直接作为疫苗,减少了蛋白纯化,除内毒素等步骤,节约了成本有利于大规模生产。
9.110951756Nucleotide acid sequences expressing SARS-CoV-2 virus antigen peptide and application of nucleotide acid sequences
CN 03.04.2020
Int.Class C12N 15/50
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
50Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
Appl.No 202010110070.8 Applicant GUANGZHOU NBIOMED MEDICINE TECHNOLOGY CO., LTD. Inventor CHEN LING
The invention discloses nucleotide acid sequences expressing SARS-CoV-2 virus antigen peptide and application of the nucleotide acid sequences. The nucleotide acid sequence comprise SEQ ID NO:1, SEQ ID NO:2 or a sequence with at least 90% homology. Nucleotide acid sequences in embodiments can be effectively expressed in human cells to produce corresponding polypeptides and produce corresponding immune protection reactions by induction, and are expected to be developed into SARS-CoV-2 vaccines.
10.WO/2020/010474THE EBOLA VIRUS GLYCOPROTEIN AS A TOOL TO STIMULATE AN IMMUNE RESPONSE
WO 16.01.2020
Int.Class C12N 15/86
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
Appl.No PCT/CA2019/050975 Applicant UNIVERSITÉ LAVAL Inventor KOBINGER, Gary
Pseudotyped vesicular stomatitis viruses comprising the Ebola virus glycoprotein and antigens, as well as viral preparations and pharmaceutical composition for generating an immune response in a host or for vaccination are provided herewith. VSV-based vectors for preparing pseudotyped vesicular stomatitis viruses comprising the Ebola virus glycoprotein and antigens are also provided.